Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

Daniel G. Wright, MD, Elizabeth C. Wright, PhD MPH, Constance Tom Noguchi, PhD

Blood (2019) 134 (Supplement_1): 1034.

https://doi.org/10.1182/blood-2019-126650

Published: 2019

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 4397.

https://doi.org/10.1182/blood.V122.21.4397.4397

Published: 2013

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 676.

https://doi.org/10.1182/blood.V122.21.676.676

Published: 2013

Journal Articles

Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival

Youssef Sorour, Stephen J Webber, Josh G Wright, Nicholas J Morley, John T Reilly, Christopher D Dalley, John A Snowden

Blood (2008) 112 (11): 2391.

https://doi.org/10.1182/blood.V112.11.2391.2391

Published: 2008

Journal Articles

Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP.

N.A. Johnson, T. Nayar, S.S. Dave, G. Wright, A. Rosenwald, W.C. Chan, M. Bast, L.M. Rimsza, H. Holte, J. Delabie, J.M. Connors, A. Al-Tourah, L. Colomo, E. Campo, T.A. Lister, D. O’Shea, L.M. Staudt, Randy D. Gascoyne

Blood (2007) 110 (11): 2606.

https://doi.org/10.1182/blood.V110.11.2606.2606

Published: 2007

Journal Articles

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65

David C. Seldin, Jennifer J. Anderson, Martha Skinner, Karim Malek, Daniel G. Wright, Karen Quillen, Kathleen Finn, Betul Oran, Vaishali Sanchorawala

Blood (2006) 108 (12): 3945–3947.

https://doi.org/10.1182/blood-2006-06-029728

Published: 2006

Journal Articles

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Laura M. Dember, MD, John L. Berk, MD, Kathleen T. Finn, RN, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2006) 108 (11): 612.

https://doi.org/10.1182/blood.V108.11.612.612

Published: 2006

Journal Articles

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

Vaishali Sanchorawala, Daniel G. Wright, Michael Rosenzweig, Kathleen T. Finn, Salli Fennessey, Jerome B. Zeldis, Martha Skinner, David C. Seldin

Blood (2006) 109 (2): 492–496.

https://doi.org/10.1182/blood-2006-07-030544

Published: 2006

Journal Articles

Gene Expression Distinguishes Burkitt Lymphoma from Other Aggressive Lymphomas and Identifies Patients Who Are Highly Curable with Intensive Chemotherapeutic Regimens.

Blood (2005) 106 (11): 415.

https://doi.org/10.1182/blood.V106.11.415.415

Published: 2005

Journal Articles

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Cynthia A. Kos, MA, Jennifer E. Ward, Karim Malek, MD, Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Carl O’Hara, MD, Lawreen Connors, Ph.D, Martha Skinner, MD, David C. Seldin, MD

Blood (2005) 106 (11): 4078.

https://doi.org/10.1182/blood.V106.11.4078.4078

Published: 2005

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Catherine Fisher, RN, Martha Skinner, MD, David C. Sedlin, MD, PhD

Blood (2005) 106 (11): 1160.

https://doi.org/10.1182/blood.V106.11.1160.1160

Published: 2005

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Karin I. Weichman, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Michael Rosenzweig, MD, Laura M. Dember, MD, Martha Skinner, MD, Daniel G. Wright, MD, Vaishali Sanchorawala, MD

Blood (2005) 106 (11): 5476.

https://doi.org/10.1182/blood.V106.11.5476.5476

Published: 2005

Journal Articles

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, Daniel G. Wright, MD, Martha Skinner, MD, Kathleen T. Finn, RN, NP, Rodney H. Falk, MD

Blood (2004) 104 (11): 2393.

https://doi.org/10.1182/blood.V104.11.2393.2393

Published: 2004

Journal Articles

Effective Delivery of Antisense Peptide Nucleic Acid Oligomers into Cells by Anthrax "Protective Antigen".

Ying Zhang, PhD, John R. Murphy, PhD, Daniel G. Wright, MD

Blood (2004) 104 (11): 5256.

https://doi.org/10.1182/blood.V104.11.5256.5256

Published: 2004

Journal Articles

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Karen Quillen, MD, Daniel G. Wright, MD, David C. Seldin, MD PhD, Martha Skinner, MD, Karim Malek, MD, Kathleen T. Finn, RN, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 5226.

https://doi.org/10.1182/blood.V104.11.5226.5226

Published: 2004

Journal Articles

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

David Cary Seldin, MD, PhD, Jennifer J. Anderson, PhD, Martha Skinner, MD, Karim Malek, MD, Daniel G. Wright, MD, Karen Quillen, MD, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 923.

https://doi.org/10.1182/blood.V104.11.923.923

Published: 2004

Journal Articles

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Barbarajean Magnani, MD, PhD, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2004) 104 (11): 942.

https://doi.org/10.1182/blood.V104.11.942.942

Published: 2004

Journal Articles

Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma.

Blood (2004) 104 (11): 701.

https://doi.org/10.1182/blood.V104.11.701.701

Published: 2004

Journal Articles

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation

David C. Seldin, Jennifer J. Anderson, Vaishali Sanchorawala, Karim Malek, Daniel G. Wright, Karen Quillen, Kathleen T. Finn, John L. Berk, Laura M. Dember, Rodney H. Falk, Martha Skinner

Blood (2004) 104 (6): 1888–1893.

https://doi.org/10.1182/blood-2004-01-0089

Published: 2004

Includes: Supplemental data

Journal Articles

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

Elie B. Choufani, Vaishali Sanchorawala, Timothy Ernst, Karen Quillen, Martha Skinner, Daniel G. Wright, David C. Seldin

Blood (2001) 97 (6): 1885–1887.

https://doi.org/10.1182/blood.V97.6.1885

Published: 2001

NARROW

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival

Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP.

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

Gene Expression Distinguishes Burkitt Lymphoma from Other Aggressive Lymphomas and Identifies Patients Who Are Highly Curable with Intensive Chemotherapeutic Regimens.

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Effective Delivery of Antisense Peptide Nucleic Acid Oligomers into Cells by Anthrax "Protective Antigen".

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma.

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only